103 related articles for article (PubMed ID: 1447706)
1. Disposition of a new diacid angiotensin-converting enzyme inhibitor after intravenous administration of drug or prodrug to monkeys and dogs.
Stuhler JD; Cheng H; Dorrbecker BR
J Pharm Sci; 1992 Nov; 81(11):1071-3. PubMed ID: 1447706
[TBL] [Abstract][Full Text] [Related]
2. Disposition and metabolism of the angiotensin-converting enzyme inhibitor [4S-[4 alpha, 7 alpha, (R*), 12b beta]]-7-[S-(1-ethoxycarbonyl-3- phenylpropyl)amino]-1,2,3,4,6,7,8,12b-octahydro-6-oxo- pyrido[2,1-a][2]benzazepine-4-carboxylic acid in monkeys and dogs.
Cheng H; Stuhler JD; Dorrbecker BR; Gordon WP
Drug Metab Dispos; 1991; 19(1):212-7. PubMed ID: 1673401
[TBL] [Abstract][Full Text] [Related]
3. Bioavailability of repeated oral administration of MDL 100,240, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase in healthy volunteers.
Rousso P; Buclin T; Nussberger J; Brunner-Ferber F; Brunner HR; Biollaz J
Eur J Clin Pharmacol; 2000 Jan; 55(10):749-54. PubMed ID: 10663454
[TBL] [Abstract][Full Text] [Related]
4. Mass balance study of [14C]M100240, a dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, in healthy male subjects.
Shah B; Emmons G; Rohatagi S; Martin NE; Jensen BK
Am J Ther; 2003; 10(5):356-62. PubMed ID: 12975720
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of M100240 and MDL 100,173, a dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, in healthy young and elderly volunteers.
Emmons GT; Argenti R; Martin LL; Martin NE; Jensen BK
J Clin Pharmacol; 2004 Aug; 44(8):901-5. PubMed ID: 15286094
[TBL] [Abstract][Full Text] [Related]
6. Quantification of a dual angiotensin I-converting enzyme-neutral endopeptidase inhibitor and the active thiol metabolite in dog plasma by high-performance liquid chromatography with ultraviolet absorbance detection.
Heath TG; Massad DD; Carroll JI; Mathews BS; Chang J; Scott DO; Kuo BS; Toren PC
J Chromatogr B Biomed Appl; 1995 Aug; 670(1):91-101. PubMed ID: 7493089
[TBL] [Abstract][Full Text] [Related]
7. The effect of food on the pharmacokinetics of a dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, M100240.
Cirillo I; Martin NE; Brennan B; Barrett JS
J Clin Pharmacol; 2004 Dec; 44(12):1379-84. PubMed ID: 15545308
[TBL] [Abstract][Full Text] [Related]
8. Interaction of angiotensin I-converting enzyme with two potent tricyclic inhibitors.
Giroux E; Beight DW; Dage RC; Flynn GA
J Enzyme Inhib; 1989; 2(4):269-77. PubMed ID: 2542490
[TBL] [Abstract][Full Text] [Related]
9. Dual ACE and NEP inhibitors: a review of the pharmacological properties of MDL 100240.
Rossi GP
Cardiovasc Drug Rev; 2003; 21(1):51-66. PubMed ID: 12595917
[TBL] [Abstract][Full Text] [Related]
10. Metabolic fate of the new angiotensin-converting enzyme inhibitor imidapril in animals. 6th communication: interspecies comparison of pharmacokinetics and excretion of imidapril metabolites in rats, dogs, and monkeys.
Yamada Y; Endo M; Kohno M; Otsuka M; Takaiti O
Arzneimittelforschung; 1992 Apr; 42(4):499-506. PubMed ID: 1642673
[TBL] [Abstract][Full Text] [Related]
11. The disposition of [14C]-labelled benazepril HCl in normal adult volunteers after single and repeated oral dose.
Waldmeier F; Kaiser G; Ackermann R; Faigle JW; Wagner J; Barner A; Lasseter KC
Xenobiotica; 1991 Feb; 21(2):251-61. PubMed ID: 2058180
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of the angiotensin converting enzyme inhibitor benazepril.HCl (CGS 14 824 A) in healthy volunteers after single and repeated administration.
Kaiser G; Ackermann R; Brechbühler S; Dieterle W
Biopharm Drug Dispos; 1989; 10(4):365-76. PubMed ID: 2758102
[TBL] [Abstract][Full Text] [Related]
13. Characterization of a dual inhibitor of angiotensin I-converting enzyme and neutral endopeptidase.
French JF; Flynn GA; Giroux EL; Mehdi S; Anderson B; Beach DC; Koehl JR; Dage RC
J Pharmacol Exp Ther; 1994 Jan; 268(1):180-6. PubMed ID: 8301555
[TBL] [Abstract][Full Text] [Related]
14. Pharmacoscintigraphic assessment of the regional drug absorption of the dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, M100240, in healthy volunteers.
Martin NE; Collison KR; Martin LL; Tardif S; Wilding I; Wray H; Barrett JS
J Clin Pharmacol; 2003 May; 43(5):529-38. PubMed ID: 12751274
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of the active metabolite of benazepril, benazeprilat, and inhibition of plasma angiotensin-converting enzyme activity after single and repeated administrations to dogs.
King JN; Mauron C; Kaiser G
Am J Vet Res; 1995 Dec; 56(12):1620-8. PubMed ID: 8599524
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic/Pharmacodynamic Modeling of Renin-Angiotensin Aldosterone Biomarkers Following Angiotensin-Converting Enzyme (ACE) Inhibition Therapy with Benazepril in Dogs.
Mochel JP; Fink M; Peyrou M; Soubret A; Giraudel JM; Danhof M
Pharm Res; 2015 Jun; 32(6):1931-46. PubMed ID: 25446774
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of the angiotensin-converting-enzyme inhibitor, benazepril, and its active metabolite, benazeprilat, in dog.
King JN; Maurer M; Morrison CA; Mauron C; Kaiser G
Xenobiotica; 1997 Aug; 27(8):819-29. PubMed ID: 9293618
[TBL] [Abstract][Full Text] [Related]
18. Disposition of 8-methyl-8-azabicyclo[3,2,1]octan-3-yl 3,5-dichlorobenzoate, a potent 5-hydroxytryptamine antagonist, and two metabolites in dogs and monkeys.
Cheng H; Larsen DL; Ragner JA; Sproles GD; Gordon WP
J Pharm Sci; 1992 Apr; 81(4):345-7. PubMed ID: 1501070
[TBL] [Abstract][Full Text] [Related]
19. Species and organ differences in first-pass metabolism of the ester prodrug L-751,164 in dogs and monkeys. In vivo and in vitro studies.
Prueksaritanont T; Gorham LM; Ellis JD; Fernandez-Metzler C; Deluna P; Gehret JR; Strong KL; Hochman JH; Askew BC; Duggan ME; Gilbert JD; Lin JH; Vyas KP
Drug Metab Dispos; 1996 Nov; 24(11):1263-71. PubMed ID: 8937862
[TBL] [Abstract][Full Text] [Related]
20. MDL 100240.
Drugs R D; 1999 Apr; 1(4):348-9. PubMed ID: 10566061
[No Abstract] [Full Text] [Related]
[Next] [New Search]
